Work

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-166846

Authors: Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, John Palcza, Pallavi Pillai, Akash Nahar, John Timmerman

Institutions: Jewish General Hospital, Hadassah Medical Center, University Hospital Cologne, Monash Health, Monash University, City Of Hope National Medical Center, CancerCare Manitoba, University of Manitoba, University Hospital Leipzig, Dana-Farber Cancer Institute, Sheba Medical Center, The University of Sydney, Tel Aviv Sourasky Medical Center, Princess Alexandra Hospital, Princess Margaret Cancer Centre, Merck & Co., Inc., Rahway, NJ, USA (United States), Ronald Reagan UCLA Medical Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310103279

FWCI: 0.508

Cites:

Cited by: 4

Related to: 10